Thank you for your interest in viewing the FDA approves Radicava - What do we need to know? webinar! Please join us on May 10, 2017 at 6:00 PM - 6:00 PM EDT
The Food and Drug Administration announced today it has granted approval to MT Pharma America to begin marketing edaravone as a treatment for amyotrophic lateral sclerosis (ALS). The approval of edaravone marks the first new treatment to be approved for ALS in the United States since Rilutek® (Riluzole) was approved in 1995. This webinar will discuss what this important announcement means for people living with ALS today.
Visit us in Cambridge, MA
Can't Make it to the Lab?
We would still love to share our lab with you. Learn more about our machines, space, and research online.